105 results
424B3
RGBP
Regen BioPharma Inc
24 Apr 24
Prospectus supplement
1:28pm
of the Company’s products, capital expenditures, financing needs, as well assumptions related to the forgoing. For this purpose, any statements contained
424B3
RGBP
Regen BioPharma Inc
19 Jan 24
Prospectus supplement
1:29pm
. For this purpose, any statements contained in this Quarterly Report that are not statement of historical fact may be deemed to be forward-looking
424B3
RGBP
Regen BioPharma Inc
20 Nov 23
Prospectus supplement
9:38am
Corporation, an FDA Specialist Group and Global Regulatory and Scientific Experts, for the purpose of review and guidance with regard to the planned … Regulatory and Scientific Experts, for the purpose of review and guidance with regard to the planned reinstatement of the Company’s inactive Investigational
424B3
mfbw612
2 Oct 23
Prospectus supplement
1:42pm
8-K
EX-10.1
ighgcpxhyqmfyz ov1
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-10.4
x665 7udhz6o9107
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-10.3
nowxiuvhb3 r8ei
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-10.2
ou4u355p8wpzf
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
424B3
nofuua z5g6f9vq1xc
15 May 23
Prospectus supplement
10:25am